TABLE 1.
Clinical trials in glioblastoma (GBM) using tyrosine kinase inhibitors (TKIs).
| Title | Condition or Disease | Intervention/Treatment | NCT Number | Status | Status Phase |
| mTORC1/mTORC2 kinase inhibitor AZD2014 in previously treated glioblastoma multiforme | Glioblastoma multiforme | Drug: AZD2014 | NCT02619864 | Completed | Phase I |
| Gefitinib and radiation therapy in treating patients with glioblastoma multiforme | Adult giant cell Glioblastoma Adult glioblastoma Adult gliosarcoma | Drug: Gefitinib | NCT00052208 | Completed | Phase I, II |
| Study of AEE788 in patients with recurrent/relapse glioblastoma multiforme (GBM) | Glioblastoma multiforme | Drug: AEE788 | NCT00116376 | Completed | Phase I, II |
| Clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma | Recurrent glioblastoma (WHO-grade IV glioma) | Drug: Axitinib Drug: Avelumab | NCT03291314 | Completed | Phase II |
| AZD8055 for adults with recurrent gliomas | Glioblastoma Multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Malignant glioma Brainstem glioma | Drug: AZD8055 | NCT01316809 | Completed | Phase I |
| Sunitinib in treating patients with recurrent malignant gliomas | Astrocytoma Adult diffuse astrocytoma Adult giant cell Glioblastoma Adult glioblastoma and other 5 | Drug: Sunitinib malate | NCT00499473 | Completed | Phase II |
| Study to assess safety, pharmacokinetics, and efficacy of oral CC-223 for patients with advanced solid tumors, non-hodgkin lymphoma or multiple myeloma | Multiple myeloma Diffuse large B cell Lymphoma Glioblastoma multiforme Hepatocellular carcinoma and other 4 | Drug: CC-223 | NCT01177397 | Completed | Phase I, II |
| Trial of ponatinib in patients with bevacizumab-refractory glioblastoma | Glioblastoma | Drug: Ponatinib | NCT02478164 | completed | Phase II |
| A phase II exploratory, multicentre, open-label, non-comparative study of ZD1839 (iressa) and radiotherapy in the treatment of patients with glioblastoma multiforme | Glioblastoma | Drug: Gefitinib | NCT00238797 | Completed | Phase II |
| A study of the safety and efficacy of tarceva in patients with first relapse of grade IV glioma (glioblastoma multiforme) | Glioblastoma | Drug: Erlotinib HCl (OSI-774) | NCT00337883 | Completed | Phase II |
| Study of tesevatinib monotherapy in patients with recurrent glioblastoma | Glioblastoma Recurrent glioblastoma Brain tumor | Drug: Tesevatinib | NCT02844439 | Completed | Phase II |
| Oral tarceva study for recurrent/residual glioblastoma multiforme and anaplastic astrocytoma | Glioblastoma multiforme Anaplastic astrocytoma | Drug: Erlotinib | NCT00301418 | Completed | Phase I, II |
| Gefitinib in treating patients with newly diagnosed glioblastoma multiforme | Adult giant cell glioblastoma Adult glioblastoma Adult gliosarcoma | Drug: Gefitinib | NCT00014170 | Completed | Phase II |
| Erlotinib and sorafenib in treating patients with progressive or recurrent glioblastoma multiforme | Adult giant cell glioblastoma Adult glioblastoma Adult gliosarcoma Recurrent adult brain tumor | Drug: erlotinib hydrochloride Drug: sorafenib tosylate | NCT00445588 | Completed | Phase II |
| AZD2171 in treating patients with recurrent glioblastoma multiforme | Adult giant cell Glioblastoma Adult glioblastoma Adult gliosarcoma Recurrent adult brain tumor | Drug: cediranib maleate | NCT00305656 | Completed | Phase II |
| Dasatinib in treating patients with recurrent glioblastoma multiforme or gliosarcoma | Adult giant cell glioblastoma Adult glioblastoma Adult gliosarcoma Recurrent adult brain neoplasm | Drug: Dasatinib | NCT00423735 | Completed | Phase II |
| Cediranib maleate and cilengitide in treating patients with progressive or recurrent glioblastoma | Adult giant cell Glioblastoma Adult glioblastoma Adult gliosarcoma Recurrent adult brain neoplasm | Drug: Cediranib maleate Drug: Cilengitide | NCT00979862 | Completed | Phase I |
| Sorafenib in newly diagnosed high grade glioma | Glioblastoma Gliosarcoma Anaplastic astrocytoma Anaplastic oligoastrocytoma Anaplastic oligodendroglioma | Drug: Sorafenib dose escalation | NCT00884416 | Completed | Phase I |
| E7050 in combination with E7080 in subjects with advanced solid tumors (dose escalation) and in subjects with recurrent glioblastoma or unresectable stage III or stage IV melanoma after prior systemic therapy (expansion cohort and phase 2) | Advanced solid tumors | Drug: E7050 Drug: Lenvatinib | NCT01433991 | Completed | Phase I, II |
| ZD 1839 in treating patients with glioblastoma multiforme in first relapse | Brain and central nervous system tumors | Drug: Gefitinib | NCT00016991 | Completed | Phase II |
| Ph I dasatinib + erlotinib in recurrent MG | Glioblastoma, Gliosarcoma | Drug: Erlotinib and dasatinib | NCT00609999 | Completed | Phase I |
| Bafetinib in treating patients with recurrent high-grade glioma or brain metastases | Adult anaplastic astrocytoma Adult anaplastic Ependymoma Adult anaplastic Oligodendroglioma Adult giant cell glioblastoma Adult glioblastoma and other 5 | Drug: Bafetinib | NCT01234740 | Completed | Phase I |
| A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma | Glioblastoma multiforme | Drug: Axitinib Drug: Axitinib plus lomustine | NCT01562197 | Completed | Phase II |
| Cediranib in combination with lomustine chemotherapy in recurrent glioblastoma | Recurrent glioblastoma | Drug: Cediranib Drug: Lomustine chemotherapy Drug: Placebo Cediranib | NCT00777153 | Completed | Phase III |
| Radiation therapy and temozolomide followed by temozolomide plus sorafenib for glioblastoma multiforme | Glioblastoma multiforme | Drug: Temozolomide Drug: Sorafenib | NCT00544817 | Completed | Phase II |
| PTK787/ZK 222584 in combination with temozolomide and radiation in patients with glioblastoma taking enzyme-inducing anti-epileptic drugs | Glioblastoma | Drug: PTK787/ZK 222584 Drug: Temozolomide | NCT00385853 | Completed | Phase I |
| Study of imatinib mesylate in combination with hydroxyurea versus hydroxyurea alone as an oral therapy in patients with temozolomide resistant progressive glioblastoma | Glioblastoma multiforme Astrocytoma | Drug: Imatinib mesylate Drug: Hydroxyurea | NCT00154375 | Completed | Phase III |
| Open label trial to explore safety of combining afatinib (BIBW 2992) and radiotherapy with or without temozolomide in newly diagnosed glioblastoma multiform | Glioblastoma | Drug: Temozolomide Drug: BIBW2992 | NCT00977431 | Completed | Phase I |
| Ph. 2 sorafenib + protracted temozolomide in recurrent GBM | Recurrent glioblastoma Multiforme | Drug: Sorafenib and temozolomide | NCT00597493 | Completed | Phase II |
| Erlotinib and temozolomide with radiation therapy in treating patients with glioblastoma multiforme or other brain tumors | Adult giant cell glioblastoma Adult glioblastoma Adult gliosarcoma | Drug: Erlotinib hydrochloride Drug: Temozolomide | NCT00039494 | Completed | Phase II |
| Erlotinib and radiation therapy in treating young patients with newly diagnosed glioma | Brain and central nervous system tumors | Drug: Erlotinib hydrochloride | NCT00124657 | Completed | Phase I, II |
| Safety and efficacy study of tarceva, temodar, and radiation therapy in patients with newly diagnosed brain tumors | Glioblastoma multiforme Gliosarcoma | Drug: Tarceva Drug: Temodar | NCT00187486 | Completed | Phase II |
| Study of sunitinib before and during radiotherapy in newly diagnosed biopsy-only glioblastoma patients | Glioblastoma | Drug: Sunitinib | NCT01100177 | Completed | Phase II |
| Dasatinib and bevacizumab in treating patients with recurrent or progressive high-grade glioma or glioblastoma multiforme | Glioblastoma multiforme | Biological: Bevacizumab Drug: Basatinib | NCT00892177 | Completed | Phase II |
| Lapatinib in treating patients with recurrent glioblastoma multiforme | Brain and central nervous system tumors | Drug: Lapatinib ditosylate | NCT00099060 | Completed | Phase I, II |
| Gefitinib in treating patients with recurrent or progressive CNS tumors | Brain and central nervous system tumors | Drug: Gefitinib | NCT00025675 | Completed | Phase II |
| Radiation therapy, temozolomide, and erlotinib in treating patients with newly diagnosed glioblastoma multiforme | CNS tumor Adult | Drug: Erlotinib hydrochloride Drug: Temozolomide | NCT00274833 | Completed | Phase II |
| Sunitinib tumor levels in patients not on enzyme-inducing anti-epileptic drugs undergoing debulking surgery for recurrent glioblastoma | Glioblastoma Brain tumor | Drug: Sunitinib | NCT00864864 | Completed | Early Phase I |
| Study of bevacizumab plus temodar and tarceva in patients with glioblastoma or gliosarcoma | Glioblastoma Gliosarcoma | Drug: Bevacizumab Drug: Tarceva Drug: Temozolomide | NCT00525525 | Completed | Phase II |
| A Phase II trial of sutent (sunitinib; SU011248) for recurrent anaplastic astrocytoma and glioblastoma | Anaplastic astrocytoma Glioblastoma | Drug: Sunitinib malate | NCT00606008 | Completed | Phase II |
| Cediranib, temozolomide, and radiation therapy in treating patients with newly diagnosed glioblastoma | Adult giant cell Glioblastoma Adult glioblastoma Adult gliosarcoma | Drug: Cediranib maleate Drug: Temozolomide | NCT00662506 | Completed | Phase I, II |
| Dasatinib or placebo, radiation therapy, and temozolomide in treating patients with newly diagnosed glioblastoma multiforme | Brain and central nervous system tumors | Drug: Dasatinib Drug: Temozolomide | NCT00869401 | Completed | Phase I, II |
| Erlotinib compared with temozolomide or carmustine in treating patients with recurrent glioblastoma multiforme | Brain and central nervous system tumors | Drug: Carmustine Drug: Erlotinib hydrochloride Drug: Temozolomide | NCT00086879 | Completed | Phase II |
| Sorafenib combined with erlotinib, tipifarnib, or temsirolimus in treating patients with recurrent glioblastoma multiforme or gliosarcoma | Adult giant cell glioblastoma Adult glioblastoma Adult gliosarcoma Recurrent adult brain tumor | Drug: Sorafenib tosylate Drug: Erlotinib hydrochloride Drug: Tipifarnib Drug: Temsirolimus | NCT00335764 | Completed | Phase I, II |
| Phase II Imatinib + hydroxyurea in treatment of patients with recurrent/progressive grade II low-grade glioma (LGG) | Glioblastoma Gliosarcoma | Drug: Imatinib mesylate and hydroxyurea | NCT00615927 | Completed | Phase II |
| Sorafenib tosylate and temsirolimus in treating patients with recurrent glioblastoma | Adult glioblastoma Adult gliosarcoma Recurrent adult brain neoplasm | Drug: Sorafenib tosylate Drug: Temsirolimus | NCT00329719 | Completed | Phase I, II |
| Phase I : cediranib in combination with lomustine chemotherapy in recurrent malignant brain tumor | Recurrent glioblastoma Brain tumor | Drug: Cediranib Drug: Lomustine | NCT00503204 | Completed | Phase I |
| Ph I SU011248 + irinotecan in treatment of Pts w MG | Glioblastoma | Drug: SU011248 and irinotecan | NCT00611728 | Completed | Phase I |
| Ph I zactima + imatinib mesylate and hydroxyurea for pts w recurrent malignant glioma | Glioblastoma Gliosarcoma | Drug: Zactima, gleevec, hydroxyurea | NCT00613054 | Completed | Phase I |
| Imatinib mesylate and hydroxyurea in treating patients with recurrent or progressive meningioma | Glioblastoma Gliosarcoma | Drug: Hydroxyurea Drug: Imatinib mesylate | NCT00354913 | Completed | Phase II |
| Bevacizumab and sorafenib in treating patients with recurrent glioblastoma multiforme | Brain and central nervous system tumors | Biological: Bevacizumab Drug: Sorafenib tosylate | NCT00621686 | Completed | Phase II |
| BIBW 2992 (afatinib) with or without daily temozolomide in the treatment of patients with recurrent malignant glioma | Glioma | Drug: BIBW 2992 Drug: TMZ Drug: BIBW 2992 plus TMZ | NCT00727506 | Completed | Phase II |
| Bevacizumab and erlotinib after radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma | Brain and central nervous system tumors | Drug: Bevacizumab Drug: Erlotinib hydrochloride | NCT00720356 | Completed | Phase II |
| Ph I gleevec in combo w RAD001 + hydroxyurea for Pts w recurrent MG | Glioblastoma Gliosarcoma | Drug: Gleevec, RAD001, and hydroxyurea | NCT00613132 | Completed | Phase I |
| GW572016 to treat recurrent malignant brain tumors | Glioma Brain tumor Glioblastoma multiforme GBM Gliosarcoma GS | Drug: Lapatinib ditosylate | NCT00107003 | Completed | Phase II |
| Temozolomide and radiation therapy with or without vatalanib in treating patients with newly diagnosed glioblastoma multiforme | Brain and central nervous system tumors | Drug: Temozolomide Drug: Vatalanib | NCT00128700 | Completed | Phase I, II |
| Ph II erlotinib + sirolimus for pts w recurrent malignant glioma multiforme | Glioblastoma Gliosarcoma | Drug: Erlotinib + Sirolimus | NCT00672243 | Completed | Phase II |
| Afatinib (BIBW 2992) QTcF trial in patients with relapsed or refractory solid tumors | Neoplasms | Drug: BIBW 2992 | NCT00875433 | Completed | Phase II |
| Phase (Ph) II bevacizumab + erlotinib for patients (Pts) with recurrent malignant glioma (MG) | Glioblastoma Gliosarcoma | Drug: Bevacizumab and erlotinib | NCT00671970 | Completed | Phase II |
| Everolimus and gefitinib in treating patients with progressive glioblastoma multiforme or progressive metastatic prostate cancer | Brain and central nervous system tumors Prostate cancer | Drug: Everolimus Drug: Gfitinib | NCT00085566 | Completed | Phase I, II |
| Sorafenib in treating patients with recurrent or progressive malignant glioma | Adult anaplastic astrocytoma Adult anaplastic Oligodendroglioma Adult giant cell Glioblastoma and other 2 | Drug: Sorafenib tosylate | NCT00093613 | Completed | Phase I |
| AZD7451 for recurrent gliomas | Glioblastoma multiforme | Drug: AZD7451 | NCT01468324 | Completed | Phase I |
| Gefitinib and radiation therapy in treating children with newly diagnosed gliomas | Untreated childhood anaplastic astrocytoma Untreated childhood anaplastic oligodendroglioma Untreated childhood brain stem glioma Untreated childhood giant cell glioblastoma and other 4 | Drug: Gefitinib | NCT00042991 | Completed | Phase I, II |
| Erlotinib in treating patients with recurrent malignant glioma or recurrent or progressive meningioma | Adult anaplastic astrocytoma Adult anaplastic oligodendroglioma Adult giant cell glioblastoma Adult glioblastoma and other 5 | Drug: Erlotinib hydrochloride | NCT00045110 | Completed | Phase I, II |
| Gamma-secretase inhibitor RO4929097 and cediranib maleate in treating patients with advanced solid tumors | Adult anaplastic astrocytoma Adult anaplastic ependymoma Adult anaplastic oligodendroglioma Adult brain stem glioma Adult giant cell glioblastoma Adult glioblastoma and other 41 | Secretase inhibitor RO4929097 Drug: Cediranib maleate | NCT01131234 | Completed | Phase I |
| EGFR inhibition using weekly erlotinib for recurrent malignant gliomas | Brain cancer | Drug: Erlotinib | NCT01257594 | Completed | Phase I |
| Lapatinib in treating young patients with recurrent or refractory central nervous system tumors | Recurrent childhood anaplastic Astrocytoma Recurrent childhood brain stem gliom Recurrent childhood ependymoma Recurrent childhood giant cell glioblastoma Recurrent childhood glioblastoma and other 3 | Drug: Lapatinib ditosylate | NCT00095940 | Completed | Phase I, II |
| Erlotinib in treating patients with solid tumors and liver or kidney dysfunction | Astrocytoma Adult anaplastic ependymoma Adult anaplastic oligodendroglioma | ||||
| Adult brain stem glioma Adult diffuse astrocytoma Adult ependymoblastoma Adult giant cell glioblastoma and 79 more | Drug: Erlotinib hydrochloride | NCT00030498 | Completed | Phase I | |
| ZD1839 and oral irinotecan in treating young patients with refractory solid tumors | Glioblastoma Rhabdomyosarcomas Neuroblastoma Osteosarcoma | Drug: Irinotecan, Gefitinib | NCT00132158 | Completed | Phase I |
| Apatinib in recurrent or refractory intracranial central nervous system malignant tumors | Efficacy and safety | Drug: Apatinib Drug: Temodar | NCT03660761 | Completed | Phase II |
| Bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma, or anaplastic astrocytoma | Adult grade III lymphomatoid granulomatosis Adult nasal type extranodal NK/T-cell lymphoma Anaplastic large cell lymphoma Angioimmunoblastic T-cell lymphoma | Biological: Bevacizumab Drug: Cediranib maleate | NCT00458731 | Completed | Phase I |
| Childhood burkitt lymphoma and other 56 | |||||
| Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | Adult anaplastic astrocytoma Adult anaplastic oligodendroglioma Adult diffuse astrocytoma Adult giant cell glioblastoma Adult glioblastoma and other 6 | Drug: Erlotinib Drug: Temsirolimus | NCT00112736 | Completed | Phase I, II |
| Pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma (VEG102857) | Glioma | Drug: Pazopanib Drug: Lapatinib | NCT00350727 | Completed | Phase I |
| BIBF 1120 for recurrent high-grade gliomas | Glioblastoma Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic oligoastrocytoma | Drug: BIBF 1120 | NCT01380782 | Completed | Phase II |
| Imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma | Brain and central nervous system tumors Lymphoma Lymphoproliferative disorder Small intestine cancer Unspecified childhood solid tumor, protocol specific | Drug: Imetelstat sodium | NCT01273090 | Completed | Phase I |
| Imatinib mesylate in treating patients with gliomas | Brain and central nervous system tumors | Drug: Imatinib mesylate | NCT00039364 | Completed | Phase II |
| Imatinib mesylate in treating patients with recurrent malignant glioma or meningioma | Brain and central nervous system tumors | Drug: Imatinib mesylate | NCT00010049 | Completed | Phase I, II |
| Tumor tissue analysis in patients receiving imatinib mesylate for malignant glioma | Brain and central nervous system tumors | Drug: Imatinib mesylate | NCT00401024 | Completed | Phase I |
| Imatinib mesylate, vatalanib, and hydroxyurea in treating patients with recurrent or relapsed malignant glioma | Brain and central nervous system tumors | Drug: Hydroxyurea Drug: Imatinib mesylate Drug: Vatalanib | NCT00387933 | Completed | Phase I |
| Gefitinib plus temozolomide in treating patients with malignant primary glioma | Brain and central nervous system tumors | Drug: Gefitinib Drug: Temozolomide | NCT00027625 | Completed | Phase I |
| Imatinib mesylate and temozolomide in treating patients with malignant glioma | Brain and central nervous system tumors | Drug: Imatinib mesylate Drug: Temozolomide | NCT00354068 | Completed | Phase I |
| Erlotinib and sirolimus in treating patients with Recurrent malignant glioma | Brain and central nervous system tumors | Drug: Erlotinib + Sirolimus | NCT00509431 | Completed | Phase I |
| SU5416 in treating patients with recurrent astrocytoma or mixed glioma that has not responded to radiation therapy | Brain and central nervous system tumors | Drug: Semaxanib | NCT00004868 | Completed | Phase I, II |
| Lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) | Advanced cancers | Drug: Lenalidomide Drug: Bevacizumab Drug: Sorafenib Drug: Temsirolimus Drug: Oxaliplatin Drug: Leucovorin Drug: 5-fluorouracil | NCT01183663 | Completed | Phase I |
Summarized in the Table 1 are the ongoing clinical trials present on ClinicalTrials.gov searching the keywords “glioblastoma multiforme” and “kinase inhibitor” The research has been done adding the following filters: “Completed”; “The research has been performed on October 21st, 2020.”